LDE-225

• CAT Number: I005667
• CAS Number: 956697-53-3
• Molecular Formula: C₂₆H₂₆F₃N₃O₃
• Molecular Weight: 485.5
• Purity: ≥95%
• Target: Smoothened
• Solubility: DMSO >60 mg/mL Ethanol >60 mg/mL
• Storage: 3 years -20℃ powder
• IC50: 1.3 nM/2.5 nM (Hh signaling Mouse/Human)
• IUPAC Name: N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide
• InChI: InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
• InChIKey: VZZJRYRQSPEMTK-CALCHBBNSA-N
• SMILES: CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F

LDE-225 (Cat.No:I005667) is a small molecule inhibitor that targets the hedgehog signaling pathway, which plays a crucial role in embryonic development and tissue homeostasis. LDE-225 specifically inhibits the smoothened (SMO) receptor, preventing the activation of downstream signaling pathways. It has shown promise as a potential treatment for various cancers, including basal cell carcinoma and medulloblastoma.

Reference

[1]. Pan SF, et al. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist ACS Med. Chem. Lett., 2010, 1 (3), 130–134. 





[2]. Fendrich V, et al. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Ann Surg, 2011, 254(5), 818-23.